Literature DB >> 15148387

Reversal of cystic fibrosis phenotype in a cultured Delta508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion.

Paul C Zamecnik1, Malay K Raychowdhury, David R Tabatadze, Horacio F Cantiello.   

Abstract

Cystic fibrosis (CF) is a lethal genetic disorder that is due to mutations in the gene encoding the cAMP-activated anion CF transmembrane conductance regulator (CFTR) channel. A three-nucleotide base deletion (TTT), encoding phenylalanine in position 508 of the translatable CFTR sequence (accompanied by a C to T replacement immediately 5' to the deletion), accounts for approximately 75% of cases of the disease. In the present study, an oligonucleotide complex (CF4-CF6, 2'-0-methyl RNA-unmodified RNA oligonucleotide duplex, respectively) was used to restore CFTR function by insertion of missing bases in Delta508 CFTR mRNA from a cultured (Delta508) cell line. cAMP-activated whole-cell currents and Cl- transport were detected in CF4-CF6-treated, but not control Delta508, cells by patch-clamp and 6-methoxy-N-(3-sulfopropyl)quinolinium fluorescence (SPQ) quenching analyses, respectively. Further, the nucleotide addition in the deleted region of Delta508 CFTR was determined after amplification by RT-PCR. Insertion of UGU and replacement of U by C immediately 5' to the deletion site in Delta508 mRNA appear to have taken place, with phenotypic but not genotypic reversion in tissue culture of treated cells. The mechanism of insertion of nucleotides has yet to be determined.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15148387      PMCID: PMC419572          DOI: 10.1073/pnas.0401933101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals.

Authors:  P D Zamore; T Tuschl; P A Sharp; D P Bartel
Journal:  Cell       Date:  2000-03-31       Impact factor: 41.582

2.  Gene therapy. The strange case of chimeraplasty.

Authors:  Gary Taubes
Journal:  Science       Date:  2002-12-13       Impact factor: 47.728

Review 3.  RNA interference.

Authors:  Gregory J Hannon
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

Review 4.  CpG motifs: the active ingredient in bacterial extracts?

Authors:  Arthur M Krieg
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

5.  Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing.

Authors:  Xiaoming Liu; Qinshi Jiang; S Gary Mansfield; M Puttaraju; Yulong Zhang; Weihong Zhou; Jonathan A Cohn; Mariano A Garcia-Blanco; Lloyd G Mitchell; John F Engelhardt
Journal:  Nat Biotechnol       Date:  2002-01       Impact factor: 54.908

6.  Targeted gene repair in mammalian cells using chimeric RNA/DNA oligonucleotides and modified single-stranded vectors.

Authors:  H Parekh-Olmedo; K Czymmek; E B Kmiec
Journal:  Sci STKE       Date:  2001-03-13

7.  Targeted gene correction by small single-stranded oligonucleotides in mammalian cells.

Authors:  O Igoucheva; V Alexeev; K Yoon
Journal:  Gene Ther       Date:  2001-03       Impact factor: 5.250

Review 8.  Development and biological applications of chloride-sensitive fluorescent indicators.

Authors:  A S Verkman
Journal:  Am J Physiol       Date:  1990-09

9.  Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides.

Authors:  S Agrawal; S H Mayrand; P C Zamecnik; T Pederson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

Review 10.  Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic CpG DNAs.

Authors:  E R Kandimalla; F-G Zhu; L Bhagat; D Yu; S Agrawal
Journal:  Biochem Soc Trans       Date:  2003-06       Impact factor: 5.407

View more
  12 in total

Review 1.  Antisense technology: an overview and prospectus.

Authors:  Stanley T Crooke; Brenda F Baker; Rosanne M Crooke; Xue-Hai Liang
Journal:  Nat Rev Drug Discov       Date:  2021-03-24       Impact factor: 84.694

2.  AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.

Authors:  Bonnie W Ramsey; Michael J Welsh
Journal:  Am J Respir Crit Care Med       Date:  2017-05-01       Impact factor: 21.405

Review 3.  Impact of gene editing on the study of cystic fibrosis.

Authors:  Patrick T Harrison; David J Sanz; Jennifer A Hollywood
Journal:  Hum Genet       Date:  2016-06-21       Impact factor: 4.132

Review 4.  One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.

Authors:  Marjolein M Ensinck; Marianne S Carlon
Journal:  Cells       Date:  2022-06-08       Impact factor: 7.666

Review 5.  New and emerging targeted therapies for cystic fibrosis.

Authors:  Bradley S Quon; Steven M Rowe
Journal:  BMJ       Date:  2016-03-30

Review 6.  The notorious R.N.A. in the spotlight - drug or target for the treatment of disease.

Authors:  Philipp Reautschnig; Paul Vogel; Thorsten Stafforst
Journal:  RNA Biol       Date:  2016-07-14       Impact factor: 4.652

Review 7.  Evolving Mechanistic Views and Emerging Therapeutic Strategies for Cystic Fibrosis-Related Diabetes.

Authors:  John C Yoon
Journal:  J Endocr Soc       Date:  2017-10-30

8.  Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis.

Authors:  Wouter Beumer; Jim Swildens; Teresinha Leal; Sabrina Noel; Herma Anthonijsz; Geert van der Horst; Hester Kuiperij-Boersma; Marko Potman; Charlotte van Putten; Patricia Biasutto; Gerard Platenburg; Hugo de Jonge; Noreen Henig; Tita Ritsema
Journal:  PLoS One       Date:  2019-06-28       Impact factor: 3.240

Review 9.  Searching for a cure for cystic fibrosis. A 25-year quest in a nutshell.

Authors:  Barbara Bosch; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2015-11-14       Impact factor: 3.183

Review 10.  The potential of antisense oligonucleotide therapies for inherited childhood lung diseases.

Authors:  Kelly M Martinovich; Nicole C Shaw; Anthony Kicic; André Schultz; Sue Fletcher; Steve D Wilton; Stephen M Stick
Journal:  Mol Cell Pediatr       Date:  2018-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.